Use of G007-LK for Osteogenic Differentiation and Bone Regeneration

ChangeBridge: Patent Apps - Biotech (C12N)

Published November 24th, 2025

Detected March 27th, 2026

Summary

The USPTO has published patent application US20260085289A1, detailing the use of a compound known as G007-LK. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, describes G007-LK's potential to promote osteogenic differentiation of dental stem cells and aid in bone tissue regeneration.

View original document View source feed page

What changed

This document is a published patent application (US20260085289A1) from the USPTO, detailing the use of G007-LK for promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, presents in vitro and in vivo experimental data suggesting G007-LK has osteoinductive properties and could be applied as an osteogenic drug for bone regeneration.

This is a patent application, not a final rule or guidance. It signifies a disclosure of an invention and does not impose immediate compliance obligations on regulated entities. However, it indicates potential future developments in the pharmaceutical and medical device sectors related to bone regeneration therapies. Companies involved in regenerative medicine, stem cell research, or bone graft materials should monitor the progression of this patent and related technologies.

Source document (simplified)

← USPTO Patent Applications

USE OF G007-LK IN PROMOTING OSTEOGENIC DIFFERENTIATION OF DENTAL MESENCHYMAL STEM CELLS

Application US20260085289A1 Kind: A1 Mar 26, 2026

Assignee

HOSPITAL OF STOMATOLOGY, GUANGZHOU MEDICAL UNIVERSITY

Inventors

Jianwen LI, Yunyang LI, Yunqin YAN, Xi XIANG, Lingling OU, Sujuan ZENG, Chaoyang MA, Bo PENG, Xuguang GAO, Janak lal PATHAK

Abstract

Disclosed is a use of G007-LK in promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. In vitro experiments of the present application show that G007-LK has the ability to induce SHED to form mineralized nodules and promote osteogenic differentiation; in vivo experiments show that G007-LK pretreatment of SHED for 7 days combined with Geistlich Bio-Oss® collagen bone scaffold can enhance the in vivo osteogenic effect of SHED and promote the subcutaneous ectopic osteogenesis of nude mice, indicating that G007-LK has good osteoinductivity and is a potential osteogenic drug. Therefore, G007-LK can promote osteogenic differentiation of dental mesenchymal stem cells and be applied to bone tissue regeneration.